Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Coding Corner Questions: Using NP/PA Services in Practice

From the College  |  Issue: February 2020  |  February 13, 2020

Scenario 1: Direct Billing

A 70-year-old female patient with rheumatoid arthritis in multiple joints and positive rheumatoid factor returns to the practice for her fourth infusion of infliximab with the nurse practitioner (NP). She reports no fevers, cough, dyspnea or concurrent illness. She rates the severity of her joint pain at 6 on a 10-point scale. The patient is currently on a non-steroidal anti-inflammatory drug (NSAID), weekly methotrexate subcutaneous injections, folic acid and famotidine. No changes were made in the patient’s medications. The patient’s weight is 130 lbs.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The patient is administered 50 mg of diphenhydramine as a prophylactic against a possible drug reaction to infliximab. Her IV line is started at 10 a.m. The intravenous infliximab 300 mg by infusion is started at 10:15 a.m. and ends at 12:26 p.m.

Is billing this service allowable under Medicare nonphysician rules?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A. Yes
B. No
C. Maybe

Scenario 2: Incident-to Billing

A 66-year-old male patient with rheumatoid arthritis in multiple joints and positive rheumatoid factor returns to the practice for his fifth infliximab infusion with the physician assistant (PA). The rheumatologist is in the practice acting as the supervising physician. The patient reports no fevers, cough, dyspnea or concurrent illness. He rates the severity of his joint pain at 7 on a 10-point scale. The patient is currently on an NSAID and weekly methotrexate subcutaneous injections. No changes were made in the patient’s medications. The patient’s weight is 265 lbs.

The patient is administered 50 mg of diphenhydramine as a prophylactic measure against a possible drug reaction to infliximab. His IV line is started at 10 a.m. The intravenous infliximab 600 mg by infusion is started at 10:05 a.m. and ends at 11:14 a.m.

Is billing this service allowable under Medicare nonphysician rules?

A. Yes
B. No
C. Maybe

Click here for the answer(s).

Share: 

Filed under:Billing/CodingFrom the College Tagged with:Medicarenurse practitionerphysician assistant

Related Articles

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    August 16, 2019

    Jarun Ontakrai / shutterstock.com Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and…

    Practice Page: Is In-house or Outsourced Medical Billing Right for Your Physician Practice?

    February 1, 2014

    What to consider when deciding whether to delegate claims billing in-house or to contract with an outside company

    Reading Rheum

    July 1, 2007

    Handpicked Reviews of Contemporary Literature

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    September 8, 2016

    paulista/shutterstock.com The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences